The generalisability of pharmacoeconomic studies

PharmacoEconomics

Volumn 11, Issue 6, 1997, Pages 503-514

  Mason, James ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC ASPECT; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW;

EID: 0030738082     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711060-00001     Document Type: Review

References (61)

1. Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee: including submissions involving economic analysis. Canberra: Australian Government Publishing Service, 1992
2. Aristides M, Mitchell A. Applying the Australian guidelines for the reimbursement of pharmaceuticals. Pharmacoeconomics 1994; 6: 196-201
3. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa: CCOHTA, 1994.
4. Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 1993; 3: 354-61
5. Leaf A. Cost-effectiveness as a criterion for Medicare coverage. N Engl J Med 1989; 321: 898-900
6. Williams AH. The cost-benefit approach. Br Med Bull 1974; 30: 252-6
7. Weinstein M, Stason W. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716-21
8. Drummond MF. Principles of economic evaluation in health care. Oxford: Oxford University Press, 1980
9. Warner KE, Luce BR. Cost-benefit and cost-effectiveness analysis in health care. Ann Arbor (MI): Health Administration Press, 1982
10. Drummond ME, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987
11. Luce BR, Elixhauser A. Standards for socio-economic evaluation of health care products and services. Berlin: Springer-Verlag, 1990
12. Kamlet MS. A framework for cost-utility analysis of government health care programs. Report to the Office of Disease Prevention and Health Promotion. Washington (DC): Public Health Service, Department of Health and Human Services in cooperation with the Foundation for Health Services Research, 1990
13. Drummond M, Brandt A, Luce B, et al. Standardizing economic evaluation methodologies in health care: practice, problems and potential. Int J Technol Assess Health Care 1993; 9: 26-36
14. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analysis in the medical literature: are methods being used correctly? Ann Intern Med 1992; 116: 238-44
15. Mason JM, Drummond MF. Reporting guidelines for economic studies. Health Econ 1995; 4: 85-94
16. Lee JT, Sanchez LA. Interpretation of 'cost-effective' and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991; 48: 2622-7
17. Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized controlled trials. Med Care 1992; 30: 231-43
18. Gerard K. Cost-utility in practice: a policy maker's guide to the state of the art. Health Policy 1992; 21: 249-79
19. Gerard K. Setting priorities in the new NHS: can purchasers use cost-utility information? Health Policy 1993; 25: 109-25
20. Department of Health, Economics and Operational Research Division. Register of cost-effectiveness studies. Leeds: Department of Health, August 1994
21. Mason JM, Drummond MF. The DH register of cost-effectiveness studies: content and quality. Health Trends 1995; 27: 50-6
22. Drummond MF, Jefferson TO, on behalf of the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-83
23. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations for reporting cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-8
24. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276: 1339-41
25. Russell IT, Devlin HB, Fell M, et al. Day-case surgery for hernias and haemorrhoids. Lancet 16 Apr 1977; 1: 844-7
26. Freemantle N, Mason JM. Publication bias in clinical trials and economic analyses. Pharmacoeconomics 1997. In press
27. Schulman KA, Glick HA, Rubin H, et al. Cost-effectiveness of HA-1A monoclonal antibody for Gram-negative sepsis: economic assessment of a new therapeutic agent. JAMA 1991; 266: 3466-71
28. Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of Gram-negative bacteraemia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 429-36
29. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 1-5
30. Schulman KA, Yabroff KR, Glick H. A health services approach for the evaluation of innovative pharmaceutical and biotechnology products. Drug Inf J 1995; 29: 1405-14
31. Yusuf S, Koon T, Woods K. Intravenous magnesium in acute myocardial infarction: an effective, sale, simple and inexpensive intervention. Circulation 1993; 87: 2043-6
32. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85
33. Egger M, Smith GD. Misleading meta analysis: lessons from 'an effective, safe, simple' intervention that wasn't. BMJ 1995; 310: 753-4
34. Freemantle N, Haines A, Mason JM, et al. CONSORT: an important step towards evidence based health care. Ann Intern Med 1997; 126: 81-3
35. Ma̧son JM, Drummond MF, Woodward EG. Optometrist screening for diabetic retinopathy: evidence and environment. Ophthalmic Physiol Opt 1996; 16: 274-85
36. Kennedy W, Reinharz D, Tessier G, et al. Cost utility of chemotherapy and best supportive care in non-small cell lung cancer. Pharmacoeconomics 1995; 8: 316-23
37. Leese B, Hutton J, Maynard A. A comparison of the costs and benefits of recombinant erythropoietin (epoietin) in the treatment of chronic renal failure in 5 European countries. Pharmacoeconomics 1992; 1: 346-56
38. Stevens ME, Summerfield GP, Hall AA, et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. BMJ 1992; 304: 474-7
39. Matheson LA, Davies L, Chisholm SO, et al. Erythropoietin in perspective. Cambridge: Daniels Publishing, 1993
40. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967; 20: 637-48
41. Simon G, VonKorff M, Heiligenstein JH. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897-902
42. Freemantle N, Long A, Mason J, et al. The treatment of depression in primary care. University of Leeds. Effective Health Care Bulletin 1993, 5: 1-12
43. Song F, Freemantle N, Sheldon T, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993, 306: 683-7
44. SOLVD Investigators. Filled of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
45. Hospital Episode Statistics 1993-94. London: Department of Health
46. Freemantle N, House A, Song F, et al. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ 1994, 309: 249-53
47. Hull RD, Hirsh J, Sackett DL, et al. Cost effectiveness of clinical diagnosis, venography and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med 1981; 304: 1561-7
48. Drummond MF, Bloom BS, Carrin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992; 8: 671-82
49. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: mullicentre, double-blind, placebo-controlled trial. Lancet 1988; 2: 1277-80
50. Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? Arch Intern Med 1994; 154: 2020-5
51. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9
52. Policy appraisal and health: a guide from the Department of Health. The Health of the Nation. London: Department of Health, 1995
53. Luce BR. Policy implications of modelling the cost-effectiveness of health care technologies. Drug Inf J 1995; 29: 1469-75
54. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1-11
55. Jonsson B, Bebbington P. What price depression? The cost of depression and the cost effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665-73
56. Jonsson B, Bebbington P. Economics of treatment of depression [authors' reply]. Br J Psychiatry 1995; 166: 398-9
57. Freemantle N, House A, Mason J, et al. Economics of treatment of depression [letter]. Br J Psychiatry 1995; 166: 397
58. Freemantle N, Maynard A. Something rotten in the state of clinical and economic analyses. Health Economics 1994; 3: 63-7
59. Woods SW, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry 1997; 170: 257-263
60. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1362-65
61. Task force on principles for economic analysis of health care technology. Economic analysis of health care technology: a report on principles. Ann Intern Med 1995; 123: 61-70